newsfilter
← Latest News
GlobeNewswire·

U.S. Patent & Trademark Office Allows AVEO Oncology's Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell Carcinoma

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with